A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.

Trial Details

NCT ID
NCT07075185
Phase
PHASE1
Sponsor
Kelonia Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • KLN-1010
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Palo Alto, California, United States|37.44188,-122.14302
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Portland, Oregon, United States|45.52345,-122.67621
  • Camperdown, New South Wales, Australia|-33.88965,151.17642

Key Eligibility Criteria

  • Participants must have relapsed and refractory multiple myeloma (RRMM) with measurable disease
  • Participants must have received at least 3 prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and CD38-…
  • Participants must have an Eastern Cooperative Group (ECOG) performance status of 0-1
  • Participants must have acceptable laboratory values as defined by the protocol

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →